Gefitinib Market Report 2024 (Global Edition)

Global Gefitinib Market Report 2024 Market Size Split by Type (10 Tables/Box, 30 Tables/Box, 90 Tables/Box), by Application (Hospital, Clinic, Drug Centre, Other)

Gefitinib Market Report Description

We have various report editions of Gefitinib Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Gefitinib Market Insights Video

Competitive Landscape of the Gefitinib Market

The competitive landscape of the gefitinib market is characterized by intense rivalry among pharmaceutical companies developing targeted therapies for non-small cell lung cancer (NSCLC). Companies compete based on drug efficacy, safety profiles, pricing strategies, and market access. Innovations such as new formulations, combination therapies, and expanded indications are key strategies to differentiate products. Regulatory approvals, clinical trial outcomes, and market expansions also play crucial roles in shaping competition within this dynamic market segment.

For instance, In October 2022, Hetero disclosed its acquisition of a brownfield manufacturing plant situated in Penjerla, Telangana, India. Spanning 55.27 acres, the facility is slated to become Hetero’s primary site for sterile pharmaceutical and biologics manufacturing, featuring advanced technological capabilities. (Source: https://www.hetero.com/press-release-2022-5)

Top Companies Market Share in Gefitinib Industry: (In no particular order of Rank)

• AstraZeneca
• Qilu Pharmaceutical
• Natco Pharma
• Celon Laboratories
• Hetero Drugs
• Dr Reddy's Laboratories
• Zuventus Healthcare
• United Biotech
• Panacea Biotec
• Cipla
• AstraZeneca
• Nobel Ilac Sanayii Ve Ticaret
• Accure Labs
• Cadila Pharmaceuticals
• Ethypharm
• Flagship Biotech International
• Globela Pharma
• Jodas Expoim
• Nishchay Pharmaceuticals
• Sichuan Xieli Pharmaceutical
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Gefitinib Market

Which Region Dominates the Gefitinib Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 due to several factors. The region boasts advanced healthcare infrastructure and early adoption of innovative treatments. High prevalence of NSCLC, stringent regulatory standards promoting early drug approvals, and robust insurance coverage contribute to extensive market penetration. Moreover, substantial investments in research and development foster continuous advancements in cancer therapies, including gefitinib. Strong physician awareness and patient advocacy further drive demand. These factors collectively reinforce North America's dominance in the gefitinib market, ensuring sustained growth and leadership in oncological treatment options.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Gefitinib market from several compelling dynamics. Increasing incidence of NSCLC due to rising tobacco use, aging populations, and environmental factors drives market expansion. Improving healthcare infrastructure and expanding access to oncological care enhance treatment uptake. Economic development and rising disposable incomes support affordability and accessibility of costly therapies like gefitinib. Moreover, advancements in diagnostic capabilities and growing awareness about personalized medicine fuel demand. Clinical trials exploring gefitinib's efficacy in diverse patient populations and regulatory reforms facilitating faster drug approvals further propel market growth in the Asia-Pacific region.

The current report Scope analyzes Gefitinib Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Gefitinib

According to Cognitive Market Research, the global gefitinib market size was estimated at USD 1541.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 616.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.

• According to Cognitive Market Research, The United States gefitinib market had a market share of USD 486.40 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. In the U.S., gefitinib sales will increase due to robust healthcare infrastructure, high incidence of NSCLC, early adoption of innovative therapies, and favorable reimbursement policies driving patient access and treatment uptake.
Canada had a market size of USD 73.98 million with a CAGR of 7.5% during the forecast period. In the U.S., gefitinib sales will increase due to robust healthcare infrastructure, high incidence of NSCLC, early adoption of innovative therapies, and favorable reimbursement policies driving patient access and treatment uptake. Mexico had a market size of USD 56.10 million with a CAGR of 7.2% during the forecast period.

Europe Gefitinib

According to Cognitive Market Research, the global Gefitinib market size was estimated at USD 1541.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 462.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• The United Kingdom had a market size of USD 77.68 million with a CAGR of 7.8% during the forecast period. The UK's gefitinib market will grow due to stringent regulatory standards promoting early drug approvals, rising prevalence of NSCLC, and investments in healthcare technologies supporting personalized treatment approaches and patient-centric care models.
France had a market size of USD 42.54 million with a CAGR of 6.2% during the forecast period. Germany had a market size of USD 91.55 million with a CAGR of 7.2% during the forecast period. Germany's gefitinib sales will increase thanks to its comprehensive healthcare system, strong emphasis on research and development in oncology, and collaborative efforts between healthcare providers and pharmaceutical companies to improve treatment outcomes. Italy had a market size of USD 39.76 million with a CAGR of 6.4% during the forecast period Russia had a market size of USD 71.67 million with a CAGR of 6.0% during the forecast period Spain had a market size of USD 37.91 million with a CAGR of 6.1% during the forecast period Luxembourg had a market size of USD 14.33 million with a CAGR of 7.1% during the forecast period Portugal had a market size of USD 9.71 million with a CAGR of 6.8% during the forecast period Greece had a market size of USD 5.55 million with a CAGR of 7.3% during the forecast period Rest of Europe had a market size of USD 71.67 million with a CAGR of 5.7% during the forecast period.

Asia Pacific Gefitinib

According to Cognitive Market Research, the global Gefitinib market size was estimated at USD 1541.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 354.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031.

• According to Cognitive Market Research, China had a market size of USD 159.51 million with a CAGR of 10.0% during the forecast period. China's gefitinib market is expanding rapidly due to economic growth, increasing healthcare investments, rising incidence of lung cancer, and government initiatives to enhance access to innovative therapies like gefitinib across diverse patient demographics.
Japan had a market size of USD 48.92 million with a CAGR of 9.0% during the forecast period India had a market size of USD 42.54 million with a CAGR of 12.3% during the forecast period. India's gefitinib sales are rising due to a growing population, improving healthcare infrastructure, rising awareness about cancer treatments, and affordability of targeted therapies, making it accessible to a larger patient base. South Korea had a market size of USD 35.45 million with a CAGR of 9.6% during the forecast period Australia had a market size of USD 18.43 million with a CAGR of 10.2% during the forecast period South East Asia had a market size of USD 24.46 million with a CAGR of 11.5% during the forecast period Rest of Asia Pacific had a market size of USD 25.17 million with a CAGR of 10.3% during the forecast period.

South America Gefitinib

According to Cognitive Market Research, the global Gefitinib market size was estimated at USD 1541.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 77.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

• According to Cognitive Market Research, Brazil had a market size of USD 32.98 million with a CAGR of 8.5% during the forecast period. Brazil's gefitinib market is growing due to improving healthcare infrastructure, rising healthcare spending, increasing prevalence of NSCLC, and advancements in oncology care facilitating better treatment options for patients.
Argentina had a market size of USD 12.95 million with a CAGR of 8.8% during the forecast period In Argentina, gefitinib sales are increasing due to expanding healthcare access, growing awareness of lung cancer treatments, and government initiatives promoting early diagnosis and treatment, supporting improved patient outcomes. Colombia had a market size of USD 6.86 million with a CAGR of 7.7% during the forecast period Peru had a market size of USD 6.32 million with a CAGR of 8.1% during the forecast period Chile had a market size of USD 5.55 million with a CAGR of 8.2% during the forecast period Rest of Latin America had a market size of USD 12.41 million with a CAGR of 7.0% during the forecast period.

Middle East and Africa Gefitinib

According to Cognitive Market Research, the global gefitinib market size was estimated at USD 1541.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 30.82 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.

• GCC Countries had a market size of USD 13.19 million with a CAGR of 9.0% during the forecast period. GCC Countries' gefitinib sales are on the rise due to high disposable incomes, increasing prevalence of lifestyle-related cancers, investments in healthcare infrastructure, and initiatives to enhance cancer care capabilities.
Egypt had a market size of USD 3.24 million with a CAGR of 8.5% during the forecast period South Africa had a market size of USD 4.87 million with a CAGR of 9.2% during the forecast period. South Africa's gefitinib market is growing due to improving healthcare access, rising incidence of NSCLC, advancements in diagnostic technologies, and efforts to address disparities in cancer treatment, ensuring broader patient access to effective therapies. Turkey had a market size of USD 2.65 million with a CAGR of 7.7% during the forecast period Nigeria had a market size of USD 3.24 million with a CAGR of 7.3% during the forecast period Rest of MEA had a market size of USD 3.64 million with a CAGR of 7.2% during the forecast period.

Gefitinib Market Analysis

Gefitinib Market Type Segment Analysis

According to Cognitive Market Research, 30 tables/box stands out as the dominating category driven by its optimal balance of treatment duration and affordability, appealing to both patients and healthcare providers. This packaging size ensures convenience in managing treatment schedules and reduces the frequency of refills, enhancing patient compliance. Additionally, established clinical protocols and physician preferences favor this standardized packaging for its practicality and ease of administration in NSCLC treatment.

90 tables/box emerges as the fastest-growing category in the gefitinib market fueled by increasing demand for cost-effective and convenient treatment options. This larger packaging size offers extended therapy durations, reducing the need for frequent refills and potentially lowering overall treatment costs. It appeals particularly to healthcare facilities managing larger patient populations and seeking efficiency in medication distribution. Moreover, patient convenience and improved adherence contribute to the rising preference for this packaging size, reflecting a trend towards optimizing healthcare resource utilization and patient outcomes in oncology care.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gefitinib Industry. Request a Free Sample PDF!

Gefitinib Market Application Segment Analysis

According to Cognitive Market Research, the dominating category is hospital due to their role as primary centers for cancer diagnosis, treatment, and management. Their comprehensive healthcare infrastructure and specialized oncology departments facilitate early diagnosis of NSCLC and prompt initiation of targeted therapies like gefitinib. Additionally, hospitals often have established protocols and access to advanced diagnostic tools, ensuring accurate patient stratification for gefitinib treatment. Collaborative multidisciplinary care teams and seamless integration of treatment modalities further enhance patient outcomes, reinforcing hospitals' central position in the gefitinib market.

The fastest-growing category in the gefitinib market is clinic due to their increasing adoption of outpatient oncology services and personalized treatment approaches. Clinics offer convenient access to gefitinib therapy, reducing logistical barriers for patients. Moreover, advancements in telemedicine and remote monitoring support ongoing patient care, enhancing treatment adherence and outcomes. The flexibility and efficiency of clinic-based care models cater to evolving patient preferences and contribute to the expanding role of clinics in delivering specialized oncology treatments like gefitinib.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion